Current Report Filing (8-k)
May 27 2021 - 5:12PM
Edgar (US Regulatory)
0000887247
false
0000887247
2021-05-23
2021-05-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 23, 2021
ADAMIS PHARMACEUTICALS CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware
|
|
0-26372
|
|
82-0429727
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
11682 El Camino Real, Suite 300
San Diego, CA
|
|
92130
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (858) 997-2400
(Former name or Former Address, if Changed Since Last
Report.)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Exchange Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock
|
|
ADMP
|
|
NASDAQ Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02.
|
Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On
May 23, 2021, the board of directors of Adamis Pharmaceuticals Corporation (the Company”) designated and appointed David C. Benedicto,
the Company’s senior director of accounting and controller, as the Company’s principal accounting officer; previously, Robert
O. Hopkins, the Company’s chief financial officer, served as the Company’s principal accounting officer. Mr. Benedicto, 60,
joined the Company in December 2014, as accounting manager. Mr. Benedicto, a CPA and CMA (Certified Management Accountant), earned a
Bachelor’s degree in Commerce from the University of Saint La Salle, and an M.B.A. from the University of the Redlands. The selection
of Mr. Benedicto to serve as principal accounting officer was not made pursuant to any arrangement or understanding with any other person.
The Company will enter into the Company’s form of indemnity agreement with Mr. Benedicto. There are no family relationships between
Mr. Benedicto and any director or executive officer of the Company, and, except as set forth above, Mr. Benedicto does not have any other
direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation
S-K.
Item 9.01
|
Financial Statements and Exhibits
|
Exhibit
No.
|
|
Description
|
|
|
|
|
104
|
|
Cover Page Interactive Data File (embedded
within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ADAMIS PHARMACEUTICALS CORPORATION
|
|
|
|
|
|
|
|
|
|
Dated: May 27, 2021
|
By:
|
/s/ Dennis J. Carlo
|
|
|
Name:
|
Dennis J. Carlo
|
|
Title:
|
Chief Executive Officer
|
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2023 to Apr 2024